MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment to patients by utilizing the immune system to recognize and kill tumor cells, and ultimately build up an immune memory response that will protect the patient from metastatic disease. Our lead candidate MBS8 has completed dose escalation studies in our phase I clinical trial with treatment of more than 80 patients at clinical sites in Denmark, Belgium and Spain.

MBS8 is a novel Lipid Nano Particle formulation with several unique selling points:

  • Due to the Lipid Nano Particle (LNP) we have increased the Therapeutic Index by more than 20 fold
  • MBS8 show more than 5 fold better anti tumor activity versus benchmark compound R848
  • Immune stimulating LNPs are engineered to reduce systemic cytokine production with a favourable safety profile
  • Administration by IV infusion is a major advantage for doctors and patients to minimize complications
  • MBS8 is an LNP incorporating a small molecule TLR7 NCE agonist
  • MBS8 show superior anti-tumor activity in preclinical models compared to many approved treatments
  • Synergy with Immune Checkpoint Inhibitors, radiotherapy and chemotherapy with complete remission in preclinical models

RECENT NEWS

MonTa announces completion of phase I does-escalation

MonTa announces completion of our phase I dose-escalation study with completion of the last cohort [...]

Read more
MonTa Biosciences Granted Broad U.S. Patent for Lead Immunotherapy Drug MBS8

We are pleased to announce that MonTa Biosciences has been granted a key U.S. patent [...]

Read more
MBS8 preclinical data published in prestigious Journal of Immunology

MonTa shares publication of MBS8 and how our TLR7 agonist demonstrates superior anti tumor activity [...]

Read more
MonTa Biosciences Secures Key Patents in Israel, China, and Japan for MBS8

We are proud to announce that MonTa Biosciences has been granted patents in Israel, China, [...]

Read more